Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Cash from Financing Activities (2019 - 2026)

Pliant Therapeutics has reported Cash from Financing Activities over the past 8 years, most recently at $74000.0 for Q1 2026.

  • Quarterly Cash from Financing Activities fell 85.14% to $74000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$32.1 million through Mar 2026, down 1858.13% year-over-year, with the annual reading at -$31.7 million for FY2025, 237.12% down from the prior year.
  • Cash from Financing Activities was $74000.0 for Q1 2026 at Pliant Therapeutics, up from -$32.3 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $273.3 million in Q1 2023 and troughed at -$32.3 million in Q4 2025.
  • The 5-year median for Cash from Financing Activities is $391000.0 (2022), against an average of $30.8 million.
  • Year-over-year, Cash from Financing Activities surged 178744.44% in 2023 and then tumbled 31734.31% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $284000.0 in 2022, then decreased by 22.89% to $219000.0 in 2023, then tumbled by 53.42% to $102000.0 in 2024, then tumbled by 31734.31% to -$32.3 million in 2025, then skyrocketed by 100.23% to $74000.0 in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Cash from Financing Activities are $74000.0 (Q1 2026), -$32.3 million (Q4 2025), and $72000.0 (Q3 2025).